Skip to main content
. 2017 Jul 13;14(4):842–858. doi: 10.1007/s13311-017-0553-8

Fig. 2.

Fig. 2

Example of patient magnetic resonance imaging (MRI) from early intravenous daclizumab trial. MRI predaclizumab and 6 months postdaclizumab intravenous monotherapy in a patient with aggressive relapsing-remitting multiple sclerosis not responding to multiple previous therapies. There is a marked reduction of (A, D) contrast-enhancing lesions with regression of lesions in the (B, E) cerebral hemispheres and (C, F) brainstem [25]